PD-1antibody plus GEMOX for klatskin tumor

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 24 Jun 2022: Trial registered, NCT05430698
  2. 31 Jan 2023: Trial started, NCT05430698

The trials

NCT05430698: PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma

State
Under way
Phase
Phase 2
People
62 planned
Started
31 Jan 2023
Primary completion
31 Jan 2027
Arms
PD-1antibody plus GEMOX
Results
None posted
  1. 24 Jun 2022: Trial registered
  2. 31 Jan 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.